Ghent University Academic Bibliography

Advanced

Biological carrier molecules of radiopharmaceuticals for molecular cancer imaging and targeted cancer therapy

An Aerts, Nathalie REN Impens, Marlies Gijs, Matthias D'huyvetter, Hans Vanmarcke, Bernard Ponsard, Tony Lahoutte, André Luxen and Sarah Baatout UGent (2014) CURRENT PHARMACEUTICAL DESIGN. 20(32). p.5218-5244
abstract
Many tumors express one or more proteins that are either absent or hardly present in normal tissues, and which can be targeted by radiopharmaceuticals for either visualization of tumor cells or for targeted therapy. Radiopharmaceuticals can consist of a radionuclide and a carrier molecule that interacts with the tumor target and as such guides the attached radionuclide to the right spot. Radiopharmaceuticals hold great promise for the future of oncology by providing early, precise diagnosis and better, personalized treatment. Most advanced developments with marketed products are based on whole antibodies or antibody fragments as carrier molecules. However, a substantial number of (pre)clinical studies indicate that radiopharmaceuticals based on other carrier molecules, such as peptides, nonimmunoglobulin scaffolds, or nucleic acids may be valuable alternatives. In this review, we discuss the biological molecules that can deliver radionuclide payloads to tumor cells in terms of their structure, the selection procedure, their (pre)clinical status, and advantages or obstacles to their use in a radiopharmaceutical design. We also consider the plethora of molecular targets existing on cancer cells that can be targeted by radiopharmaceuticals, as well as how to select a radionuclide for a given diagnostic or therapeutic product.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
non-immunoglobulin scaffolds, nucleic acids, peptides, antibody, targeted therapy, Radiopharmaceuticals, molecular imaging, RECEPTOR-EXPRESSING TUMORS, GLUCAGON-LIKE PEPTIDE-1, HER2-EXPRESSING MALIGNANT-TUMORS, HER2-SPECIFIC AFFIBODY MOLECULE, POSITRON-EMISSION-TOMOGRAPHY, CYSTINE-KNOT MINIPROTEINS, PINHOLE SPECT/MICRO-CT, NON-HODGKINS-LYMPHOMA, IN-VIVO, RADIONUCLIDE THERAPY
journal title
CURRENT PHARMACEUTICAL DESIGN
Curr. Pharm. Design
volume
20
issue
32
pages
5218 - 5244
Web of Science type
Article
Web of Science id
000342003600013
JCR category
PHARMACOLOGY & PHARMACY
JCR impact factor
3.452 (2014)
JCR rank
63/255 (2014)
JCR quartile
1 (2014)
ISSN
1381-6128
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
6854828
handle
http://hdl.handle.net/1854/LU-6854828
date created
2015-06-30 18:29:07
date last changed
2016-12-19 15:46:15
@article{6854828,
  abstract     = {Many tumors express one or more proteins that are either absent or hardly present in normal tissues, and which can be targeted by radiopharmaceuticals for either visualization of tumor cells or for targeted therapy. Radiopharmaceuticals can consist of a radionuclide and a carrier molecule that interacts with the tumor target and as such guides the attached radionuclide to the right spot. Radiopharmaceuticals hold great promise for the future of oncology by providing early, precise diagnosis and better, personalized treatment. Most advanced developments with marketed products are based on whole antibodies or antibody fragments as carrier molecules. However, a substantial number of (pre)clinical studies indicate that radiopharmaceuticals based on other carrier molecules, such as peptides, nonimmunoglobulin scaffolds, or nucleic acids may be valuable alternatives. In this review, we discuss the biological molecules that can deliver radionuclide payloads to tumor cells in terms of their structure, the selection procedure, their (pre)clinical status, and advantages or obstacles to their use in a radiopharmaceutical design. We also consider the plethora of molecular targets existing on cancer cells that can be targeted by radiopharmaceuticals, as well as how to select a radionuclide for a given diagnostic or therapeutic product.},
  author       = {Aerts, An and Impens, Nathalie REN and Gijs, Marlies and D'huyvetter, Matthias and Vanmarcke, Hans and Ponsard, Bernard and Lahoutte, Tony and Luxen, Andr{\'e} and Baatout, Sarah},
  issn         = {1381-6128},
  journal      = {CURRENT PHARMACEUTICAL DESIGN},
  keyword      = {non-immunoglobulin scaffolds,nucleic acids,peptides,antibody,targeted therapy,Radiopharmaceuticals,molecular imaging,RECEPTOR-EXPRESSING TUMORS,GLUCAGON-LIKE PEPTIDE-1,HER2-EXPRESSING MALIGNANT-TUMORS,HER2-SPECIFIC AFFIBODY MOLECULE,POSITRON-EMISSION-TOMOGRAPHY,CYSTINE-KNOT MINIPROTEINS,PINHOLE SPECT/MICRO-CT,NON-HODGKINS-LYMPHOMA,IN-VIVO,RADIONUCLIDE THERAPY},
  language     = {eng},
  number       = {32},
  pages        = {5218--5244},
  title        = {Biological carrier molecules of radiopharmaceuticals for molecular cancer imaging and targeted cancer therapy},
  volume       = {20},
  year         = {2014},
}

Chicago
Aerts, An, Nathalie REN Impens, Marlies Gijs, Matthias D’huyvetter, Hans Vanmarcke, Bernard Ponsard, Tony Lahoutte, André Luxen, and Sarah Baatout. 2014. “Biological Carrier Molecules of Radiopharmaceuticals for Molecular Cancer Imaging and Targeted Cancer Therapy.” Current Pharmaceutical Design 20 (32): 5218–5244.
APA
Aerts, An, Impens, N. R., Gijs, M., D’huyvetter, M., Vanmarcke, H., Ponsard, B., Lahoutte, T., et al. (2014). Biological carrier molecules of radiopharmaceuticals for molecular cancer imaging and targeted cancer therapy. CURRENT PHARMACEUTICAL DESIGN, 20(32), 5218–5244.
Vancouver
1.
Aerts A, Impens NR, Gijs M, D’huyvetter M, Vanmarcke H, Ponsard B, et al. Biological carrier molecules of radiopharmaceuticals for molecular cancer imaging and targeted cancer therapy. CURRENT PHARMACEUTICAL DESIGN. 2014;20(32):5218–44.
MLA
Aerts, An, Nathalie REN Impens, Marlies Gijs, et al. “Biological Carrier Molecules of Radiopharmaceuticals for Molecular Cancer Imaging and Targeted Cancer Therapy.” CURRENT PHARMACEUTICAL DESIGN 20.32 (2014): 5218–5244. Print.